Sydney, Oct 16, 2007 AEST (ABN Newswire) - Stirling Products Limited (ASX: STI) advises shareholders that studies recently conducted at the University of Western Australia have confirmed the superior biological potency of R-salbutamol over racemic salbutamol.
The biological potency of bronchodilators (of which racemic (mixed) salbutamol and the more refined R-salbutamol are examples) is most commonly assessed by measuring relaxation responses in tracheal tissue. Stirling has recently completed studies on its new raw material manufactured under a patented process in Europe. These studies confirm R-salbutamol is twice as potent as racemic salbutamol.
"The studies compared the biological activity from our most recent batch of R-salbutamol manufactured in Europe under Stirling's patented process with racemic salbutamol and a leading industry standard used in human pharmaceutical preparations", indicated Dr London, CEO and Managing Director, Stirling Products.
In vitro dose-response testing, performed in the Pharmacology and Anaesthesiology Unit of the University of Western Australia by Dr Peter Henry, demonstrated that Stirling's R-salbutamol was twice as potent as racemic salbutamol. That is, it produces the same response at half the dose. The results also indicated there was no measurable difference in potency or activity between Stirling R-salbutamol and the industry control widely used in human pharmaceuticals.
"These results produced a better than expected result for the biological activity of R-salbutamol. R-salbutamol, because of its 'chemical purity', produces a superior potency profile than racemic (mixed) salbutamol and it is as good as, if not better than, product currently manufactured by other processes and used in humans", indicated Dr London. "This is in essence, a validation of the manufacturing process and the product that is produced. It gives us continued confidence that the positive results we are seeing in all our trials are real, whether used as a growth agent in livestock, as a treatment for overweight dogs or as a treatment to relieve the symptoms of heaves in horses'.
The R-salbutamol that was tested is being used for the trials, currently being conducted by Merial Limited, for use as a growth agent in sheep and potentially cattle.
Contact
Dr London
TEL: +61-8-9480-1480
MOB: +61-400-204-616
WEB: www.stirlingproducts.net
| ||
|
